Cholesterol management in patients with IHD: An audit-based appraisal of progress towards clinical targets in primary care

British Journal of Cardiology

Volumn 10, Issue 3, 2003, Pages 223-228

  De Lusignan, Simon ^a   Dzregah, Billy ^a   Hague, Nigel ^a   Chan, Tom ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Computerised medical record; Coronary heart disease; Health informatics; Primary care; Secondary prevention

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPUTER SYSTEM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; ELECTRONIC MEDICAL RECORD; FEMALE; GENERAL PRACTICE; HEALTH CARE QUALITY; HEART DISEASE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; PREDICTION; PRESCRIPTION; PREVALENCE; PRIMARY HEALTH CARE; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; UNITED KINGDOM; VALIDATION PROCESS;

EID: 0038408588     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Department of Health. National Service Framework. Coronary Heart Disease. London: Department of Health, 2000.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
3. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: Evidence from a national cross sectional survey. BMJ 2000;321:1322-5.
4. Brady AJB, Oliver MA, Pittard JB. Secondary prevention in 24,431 patients with coronary heart disease: Survey in primary care. BMJ 2001;322:1463.
5. Whincup PH, Emberson JR, Lennon L et al. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart 2002;88:25-9.
6. Department of Health. Prescription Cost Analyses: England 1998, 1999, 2000, 2001. London: Department of Health, 1999-2002.
7. DeWilde S, Carey IM, Bremner SA et al. Evolution of statin prescribing 1994-2001: A case of agism but not of sexism? Heart 2003;89:417-21.
8. De Lusignan S, Hague NJ. The PCDQ (Primary Care Data Quality) Programme. Bandolier/Impact. January 2001. www.jr2.ox.ac.uk/Bandolier/booth/mgmt/PCDQ.html (Accessed 18.3.03).
9. Clinical Information Consultancy. MIQUEST and Health Query Language. (www.clinical-info.co.uk/miquest.htm Accessed 18.3.03).
10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
11. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
12. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-09.
13. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-07.
14. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002;360:1623-30.
15. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615-22.
16. Ross SD, Allen IE, Connelly JE et al. Clinical outcomes in statin treatment trials: A meta-analysis. Arch Intern Med 1999;159:1793-802.
17. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA 1997;278:313-21.
18. Moore RA, McQuay H. Statins. Bandolier 1998;47:2.
19. Scottish Executive. Coronary heart disease and stroke: Strategy for Scotland. Edinburgh: The Stationary Office, 2002. (www.scotland.gov.uk/library5/health/chds.pdf)
20. Welsh Assembly Government. Tackling Coronary Heart Disease in Wales. Implementing Through Evidence. Cardiff: Welsh Assembly Government, 2001.
21. Department of Health. Health Survey for England 1998: Cardiovascular Disease. London: Department of Health, 1999. (www.archive.official-documents.co.uk/document/doh/survey98/hse98.htm Accessed 18.3.03).
22. De Lusignan S, Hague N, Brown A. Improving secondary prevention in coronary heart disease in seven primary care organisations, using a learner centred knowledge management approach. In: Bryant J (ed.). Current Perspectives in Healthcare Computing. Proceedings of HC 2002. Guilford: British Computer Society, 2002;17-25.
23. Sacks FM. Adherence to statin therapy: Why aren't we doing better? Am J Med 2002;113:685-6.